These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1724 related articles for article (PubMed ID: 8553680)

  • 1. Leukocyte activation by isolated hyperthermic liver and limb perfusion due to malignancy.
    Arnestad JP; Bengtsson A; Bengtson JP; Hafström L; Redl H; Schlag G
    World J Surg; 1995; 19(6):861-6. PubMed ID: 8553680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated hyperthermic liver perfusion with cytostatic-containing perfusate activates the complement cascade.
    Arnestad JP; Bengtsson A; Bengtson JP; Henriksson BA; Stenqvist O; Naredi P; Hafström L
    Br J Surg; 1992 Sep; 79(9):948-51. PubMed ID: 1422767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan.
    Zwaveling JH; Maring JK; Clarke FL; van Ginkel RJ; Limburg PC; Hoekstra HJ; Koops HS; Girbes AR
    Crit Care Med; 1996 May; 24(5):765-70. PubMed ID: 8706451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated organ perfusion does not result in systemic microembolization of tumor cells.
    Wu PC; McCart A; Hewitt SM; Turner E; Libutti SK; Bartlett DL; Alexander HR
    Ann Surg Oncol; 1999; 6(7):658-63. PubMed ID: 10560851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    J Clin Oncol; 1996 Feb; 14(2):479-89. PubMed ID: 8636761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
    Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
    Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperthermic isolated limb perfusion increases circulating levels of inflammatory cytokines.
    Quinn TD; Polk HC; Edwards MJ
    Cancer Immunol Immunother; 1995 Apr; 40(4):272-75. PubMed ID: 7750126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs.
    Thompson JF; Gianoutsos MP
    World J Surg; 1992; 16(2):227-33. PubMed ID: 1561803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan.
    Lindnér P; Fjälling M; Hafström L; Kierulff-Nielsen H; Mattsson J; Scherstén T; Rizell M; Naredi P
    Eur J Surg Oncol; 1999 Apr; 25(2):179-85. PubMed ID: 10218462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.
    Lasithiotakis K; Economou G; Gogas H; Ioannou C; Perisynakis K; Filis D; Kastana O; Bafaloukos D; Decatris M; Catodritis N; Frangia K; Papadakis G; Magarakis M; Tsoutsos D; Chrysos E; Chalkiadakis G; Zoras O
    Oncol Rep; 2010 Apr; 23(4):1077-83. PubMed ID: 20204294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
    Kettelhack C; Hohenberger P; Schlag PM
    Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
    Kettelhack C; Hohenberger P; Schulze G; Kilpert B; Schlag PM
    Crit Care Med; 2000 Apr; 28(4):1040-6. PubMed ID: 10809279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of tissue oxygen partial pressure during isolated, hyperthermic limb perfusion with cytostatic drugs or recombinant human tumor necrosis factor alpha combined with melphalan.
    Hohenberger P; Bida B; Schlag PM
    Strahlenther Onkol; 1996 Nov; 172 Suppl 2():14-5. PubMed ID: 8946039
    [No Abstract]   [Full Text] [Related]  

  • 15. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
    Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
    Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose mitomycin C in isolated hyperthermic liver perfusion for unresectable liver metastases.
    Oldhafer KJ; Frerker MK; Lang H; Fauler J; Flemming P; Schmoll E; Nadalin S; Moreno L; Pichlmayr R
    J Invest Surg; 1998; 11(6):393-400. PubMed ID: 9895113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma.
    Paulsen IF; Chakera AH; Drejøe JB; Klyver H; Dahlstrøm K; Oturai PS; Mortensen J; Hesse B; Schmidt G; Drzewiecki K
    Dan Med J; 2014 Jan; 61(1):A4741. PubMed ID: 24393586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas.
    Rossi CR; Mocellin S; Pilati P; Foletto M; Campana L; Quintieri L; De Salvo GL; Lise M
    Ann Surg Oncol; 2005 May; 12(5):398-405. PubMed ID: 15915374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 87.